Vivimed Labs Ltd Locks at Lower Circuit With 1.9% Loss — Sellers Queue, No Buyers in Sight

Circuit Event and Unfilled Supply

The stock’s fall to Rs 6.67 represents the maximum permissible loss under its 2% price band for the day. This lower circuit event signals that supply overwhelmed demand to the extent that the exchange’s mechanism intervened to halt further decline. The total traded volume was minuscule at just 0.00021 lakh shares, with a turnover of merely ₹0.000014 crore, underscoring the extremely thin liquidity on the day. The circuit lock effectively trapped sellers who were unable to find buyers willing to transact at these levels — how deep is the exit problem for Vivimed Labs and what would need to change for normal trading to resume?

Delivery and Volume Analysis

Delivery volumes tell a nuanced story on a lower circuit day. On 1 Sep 2026, the delivery volume was 2,550 shares, which fell sharply by 84.92% compared to the 5-day average delivery volume. This decline in delivery volume suggests that the selling pressure was not driven by genuine holders offloading their stakes but rather by speculative short-selling or intraday trades. On a lower circuit, rising delivery volume would indicate capitulation and forced liquidation, but here the falling delivery volume points to a different dynamic — is this a temporary speculative move or a sign of deeper weakness?

Intraday Price Action

The stock’s intraday range was narrow, with both the high and low price recorded at Rs 6.67, the circuit floor. This indicates that the stock opened near the lower circuit and remained locked there throughout the session, with no recovery attempt. The absence of any intraday bounce or higher trading levels highlights the lack of buying interest and the dominance of sellers from the outset. This kind of price action often reflects a market where participants are unwilling to step in, leaving sellers stranded at the floor price.

Moving Averages and Trend Context

Technically, Vivimed Labs Ltd trades below its 5-day and 200-day moving averages but remains above the 20-day, 50-day, and 100-day averages. This mixed configuration suggests short-term weakness amid a longer-term sideways or mildly positive trend. The recent three-day consecutive fall, amounting to a 5.66% decline, confirms a weakening momentum. Being below the shorter-term MAs often signals immediate selling pressure, and the circuit lock at the lower band reinforces the absence of near-term support — does the technical profile of Vivimed Labs show any nearby support, or is more downside likely?

Liquidity and Market Capitalisation Context

With a market capitalisation of approximately ₹56 crore, Vivimed Labs Ltd is classified as a micro-cap stock. Such stocks typically suffer from thin liquidity, which amplifies exit risk during sharp declines. The stock’s liquidity profile is fragile, with a trade size effectively close to zero based on 2% of the 5-day average traded value. This means that any sizeable position faces severe friction in exiting without impacting the price further. The lower circuit lock compounds this problem, as sellers cannot find buyers, potentially leading to multi-day circuit locks if selling interest persists — how might this liquidity constraint affect the stock’s near-term trading dynamics?

Brief Fundamental Context

Vivimed Labs Ltd operates within the Pharmaceuticals & Drugs industry, a sector often subject to regulatory and market volatility. While fundamentals are not the focus here, the micro-cap status and sector characteristics mean that price movements can be exaggerated by liquidity and sentiment shifts rather than fundamental changes alone.

Conclusion: Severity and Liquidity Caveats

The lower circuit lock at Rs 6.67 for Vivimed Labs Ltd reflects a day where selling pressure overwhelmed demand to the point of a trading halt. The falling delivery volume suggests speculative selling rather than wholesale liquidation by holders, but the micro-cap status and extremely low liquidity raise concerns about the ability of sellers to exit positions without further price impact. The stock’s position below key short-term moving averages confirms the technical weakness that preceded the circuit event. Locked at the floor price with unfilled supply, the stock faces a liquidity trap that could prolong volatility and price stagnation — after a 1.91% single-day loss at lower circuit, is Vivimed Labs approaching oversold territory or does the selling pressure have further to run? The complete analysis weighs the data.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →